prnewswire.com

Reputation Factor: 4.0 High
Sites Owned: 1
Total Reference Links: 200
Total Citations: 625
Unique Wikipedia Articles Citing: 186

Associated Sites

www.prnewswire.com

News

Links: 200

Citations: 625

Top Reference Links

Score	Article	Site	Category	Cited In (Articles)
12.0	U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer https://www.prnewswire.com/news-releases/us-fda-approves-inluriyo-imlunestrant-for-adults-with-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer-302567490.html	www.prnewswire.com	News	3
12.0	Six Flags Over Texas Unveils Record-Breaking Roller Coaster 'Tormenta Rampaging Run;' Set to Become Tallest, Fastest, Longest and First-Ever Giga Dive Coaster https://www.prnewswire.com/news-releases/six-flags-over-texas-unveils-record-breaking-roller-coaster-tormenta-rampaging-run-set-to-become-tallest-fastest-longest-and-first-ever-giga-dive-coaster-302567286.html	www.prnewswire.com	News	3
12.0	Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) https://www.prnewswire.com/news-releases/novartis-receives-fda-approval-for-rhapsido-remibrutinib-the-only-oral-targeted-btki-treatment-for-chronic-spontaneous-urticaria-csu-302571629.html	www.prnewswire.com	News	3
12.0	Clarivate Unveils Citation Laureates 2025 - Highlighting Nobel-Class Research with Global Impact https://www.prnewswire.com/news-releases/clarivate-unveils-citation-laureates-2025--highlighting-nobel-class-research-with-global-impact-302566388.html	www.prnewswire.com	News	3
8.0	Clarivate Unveils Citation Laureates 2025 - Highlighting Nobel-Class Research with Global Impact https://www.prnewswire.com/in/news-releases/clarivate-unveils-citation-laureates-2025--highlighting-nobel-class-research-with-global-impact-302566406.html	www.prnewswire.com	News	2
8.0	Stealth BioTherapeutics Announces FDA Accelerated Approval of Forzinity (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome-302562058.html	www.prnewswire.com	News	2
8.0	Asia's Biggest Sustainability Expo Opens in September https://www.prnewswire.com/apac/news-releases/asias-biggest-sustainability-expo-opens-in-september-over-100-exhibitors-join-to-charge-towards-change-302538219.html	www.prnewswire.com	News	2
8.0	FDA Approves Brinsupri (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease https://www.prnewswire.com/news-releases/fda-approves-brinsupri-brensocatib-as-the-first-and-only-treatment-for-non-cystic-fibrosis-bronchiectasis-a-serious-chronic-lung-disease-302527941.html	www.prnewswire.com	News	2
8.0	Asian Hall of Fame Announces Nominees for Induction https://www.prnewswire.com/news-releases/asian-hall-of-fame-announces-nominees-for-induction-301808627.html	www.prnewswire.com	News	2
8.0	Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies https://www.prnewswire.com/news-releases/novo-holdings-posts-record-total-income-and-investment-returns-of-dkk-60-billion-8-0-billion-in-2024--with-the-investment-portfolio-delivering-above-benchmark-returns-alongside-strong-growth-at-the-novo-group-companies-302417950.html	www.prnewswire.com	News	2

Citation Trends Over Time